Five Texas wells pumping oil for AKK

Published 10-DEC-2014 15:27 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Austin Exploration’s (ASX: AKK) fifth well in the prolific Texas Eagle Ford has pumped out 19,600BOE in its first thirty days of operation – right as the company achieves positive cash flow and secures new funding.

AKK is developing its Texas Birch Eagle Ford project in the middle of a proven hydrocarbon basin and has now spudded six wells.

AKK’s $2.9BN market cap farm-out partner Halcon Resources has been the operator on the first three 10,000ft wells of which were free carried up to a cost of $10M per well.

The Curington “A” 1H well is the first well AKK has drilled with Halcon where costs are shared, and the sixth well, Seaducer 1H, should have results announced soon.

Curington “A” 1H pumping oil

Over 226,000BOE have been drawn by AKK from the first four wells drilled in 2014 in the Eagle Ford shale.

AKK says the fifth well, Curington “A” 1H, is flowing at a daily rate of 653BOPED with a cut of 92% oil, giving a 30-day figure of 19,600BOE. The well is also producing large volumes of gas.

AKK’s CEO and Managing Director Dr Mark Hart says the success of its five wells so far shows how prolific the Eagle Ford shale can be. “Five from five is quite something, and our sixth well, the Seaducer well, is coming along nicely,” he says.

“Fortunately, the Eagle Ford shale has the lowest production costs of any oil basin in the United States and remains profitable in this current low oil price environment.”

AKK’s Birch property in Texas can accommodate over 100 horizontal wells and the company says it wants to greatly expand its operations therein the coming years.

Cash flowing in for AKK

With five oil wells now flowing in the Texas Eagle Ford shale field and a sixth on the way, AKK says it is now cash flow positive on a monthly basis.

The regular sales of oil from its Texas operations will be used to support AKK’s other ventures in the US, such as the expansion of its Niobrara Pathfinder oil and gas project in Colorado, which is also contributing to AKK’s cash flow with regular sales of both resources.

New cornerstone investor

AKK has secured a new cornerstone investor, Lanstead Capital L.P., a UK-based institutional investor. Lanstead is investing AUD$4.513M in AKK in return for 59 million new ordinary shares, at a price of $0.0765 each, representing 19.8% equity in the company.

AKK says the proceeds will help pay for its high impact drilling programmes at its oil and gas plays across the USA, including the Eagle Ford in Texas and the Niobrara Pathfinder Project in Colorado.

This comes after AKK successfully consolidated its shares on a 10:1 basis and secured an incremental rolling facility with CHASE bank to provide cash when needed at a margin of $3.5%.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free